PDPL — Parenteral Drugs (India) Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -649.25% | ||
Financial Summary
| Year End 31st Mar | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 2,171.11 | 320.28 | 318.75 | 121.68 | 84.96 | n/a | n/a | -48.7% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Parenteral Drugs (India) Limited is engaged in the manufacturing of pharmaceutical products. It also manufactures intravenous (IV) infusion, inhalation, and veterinary infusion. It offers products in various categories, including IV fluids, oncology, anesthesia and exports. Its IV Fluids include Carbohydrated and Electrolytes, such as Dextrose IP 5%, 10%, 20%, Dextrose IP 25% , and Ringer Lactate IP; Diuretics, such as Mannitol 10%, 20% and Manidex (Mannitol 10% with Glycerine 10%); Dialysis and Irrigation Solution, such as Peritoneal Dialysis Solution with 1.7% Dextrose and 1.5% Glycine; Anti-infective and Anti-fungal, such as Ciprofloxacin 200mg and Metronidazole 500mg and others , such as Tamolgan (Paracetamol 1000mg) and PD-Invert (10% Invert Sugar). Its Oncology product mix includes 5 FU-PAR and BAZIPAR. Its Anesthesia product mix includes Sevoplan (Sevoflurane 100/250ml) and Isoplan (Isoflurane 100/250ml).
Directors
- Manohar Gupta NEC
- Pooja Choukse CCO
- Vinod Gupta MDR (65)
- Govind Garg EDR (65)
- Shree Ganesh Chambers SEC
- Anil Mittal NED (48)
- Chhaya Gupta IND
- Manish Verma IND (36)
- Dharam Khanna NID
- Dilip Sinha NID
- Last Annual
- March 31st, 2022
- Last Interim
- March 31st, 2022
- Incorporated
- December 13th, 1983
- Public Since
- September 12th, 1994
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 29,816,300
- Address
- Shree Ganesh Chambers, INDORE, 452001
- Web
- https://www.pdindia.com
- Phone
- +91 7314092000
- Contact
- Shree Ganesh Chambers
- Auditors
- Singhal Jain & Co.
Upcoming Events for PDPL
Similar to PDPL
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 22:33 UTC, shares in Parenteral Drugs (India) are trading at IN₹2.90. This share price information is delayed by 15 minutes.
Shares in Parenteral Drugs (India) last closed at IN₹2.90 and the price had moved by -18.31% over the past 365 days. In terms of relative price strength the Parenteral Drugs (India) share price has underperformed the S&P BSE 100 Index by -23.05% over the past year.
There is no consensus recommendation for this security.
Find out moreParenteral Drugs (India) does not currently pay a dividend.
Parenteral Drugs (India) does not currently pay a dividend.
Parenteral Drugs (India) does not currently pay a dividend.
To buy shares in Parenteral Drugs (India) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹2.90, shares in Parenteral Drugs (India) had a market capitalisation of .
Here are the trading details for Parenteral Drugs (India):
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: PDPL
Based on an overall assessment of its quality, value and momentum Parenteral Drugs (India) is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Parenteral Drugs (India). Over the past six months, its share price has underperformed the S&P BSE 100 Index by -25.96%.
As of the last closing price of IN₹2.90, shares in Parenteral Drugs (India) were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Parenteral Drugs (India) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹2.90.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Parenteral Drugs (India)'s management team is headed by:
- Manohar Gupta - NEC
- Pooja Choukse - CCO
- Vinod Gupta - MDR
- Govind Garg - EDR
- Shree Ganesh Chambers - SEC
- Anil Mittal - NED
- Chhaya Gupta - IND
- Manish Verma - IND
- Dharam Khanna - NID
- Dilip Sinha - NID